{"id":"peg-intron","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"40-60","effect":"Headache"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Depression/mood changes"},{"rate":"20-30","effect":"Injection site reactions"},{"rate":"10-20","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL405705","moleculeType":"Small molecule","molecularWeight":"1256.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PEG-Intron is interferon alfa-2b conjugated with polyethylene glycol (PEG), which slows clearance and extends half-life compared to unmodified interferon. It activates natural killer cells, macrophages, and T lymphocytes to suppress viral replication and has immunomodulatory effects. The pegylation allows for less frequent dosing while maintaining therapeutic efficacy.","oneSentence":"PEG-Intron is a pegylated interferon alfa-2b that enhances and prolongs the antiviral immune response by binding to interferon receptors on immune cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:13.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, in combination with ribavirin"},{"name":"Chronic hepatitis B virus (HBV) infection"}]},"trialDetails":[{"nctId":"NCT07468916","phase":"PHASE2","title":"Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-03-29","conditions":"Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":35},{"nctId":"NCT02737046","phase":"PHASE2","title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-12-12","conditions":"Adult T-cell Leukemia-Lymphoma, ATLL","enrollment":15},{"nctId":"NCT07445893","phase":"NA","title":"A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV","status":"NOT_YET_RECRUITING","sponsor":"Duan Minghui","startDate":"2026-02-24","conditions":"Polycythemia Vera (PV)","enrollment":30},{"nctId":"NCT07438093","phase":"NA","title":"Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-04","conditions":"Advanced Solid Tumors","enrollment":60},{"nctId":"NCT02948426","phase":"PHASE1","title":"Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-02-08","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer","enrollment":18},{"nctId":"NCT01466192","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Chronic Hepatitis C","enrollment":108},{"nctId":"NCT00630058","phase":"PHASE1","title":"A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT00780910","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":109},{"nctId":"NCT00780416","phase":"PHASE3","title":"Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Hepatitis C","enrollment":189},{"nctId":"NCT00781274","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT01468584","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-11","conditions":"Chronic Hepatitis C","enrollment":10},{"nctId":"NCT00539591","phase":"PHASE2","title":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-05-09","conditions":"Malignant Melanoma","enrollment":29},{"nctId":"NCT06552429","phase":"PHASE2","title":"Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2024-08-29","conditions":"Essential Thrombocythemia","enrollment":27},{"nctId":"NCT07231276","phase":"PHASE4","title":"Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01-01","conditions":"HBV, Chronic Hepatitis B Virus","enrollment":113},{"nctId":"NCT02370329","phase":"PHASE2","title":"P1101 in Treating Patients With Myelofibrosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-08-12","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":11},{"nctId":"NCT07199413","phase":"PHASE1","title":"Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03-01","conditions":"Brain Metastases, Leptomeningeal Metastasis","enrollment":20},{"nctId":"NCT07183293","phase":"NA","title":"A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Xiamen Humanity Hospital","startDate":"2025-10","conditions":"HBV-related Liver Cirrhosis","enrollment":30},{"nctId":"NCT01718301","phase":"PHASE3","title":"HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin","status":"TERMINATED","sponsor":"Anna Cruceta","startDate":"2013-03-10","conditions":"Hepatitis C, HIV Infections, COINFECTION","enrollment":108},{"nctId":"NCT07120750","phase":"","title":"Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-09-01","conditions":"Hepatocellular Carcinoma (HCC), Chronic Hepatitis B","enrollment":332},{"nctId":"NCT07071636","phase":"PHASE4","title":"Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-08-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Chronic Hepatitis B","enrollment":830},{"nctId":"NCT05182463","phase":"PHASE4","title":"Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-01-08","conditions":"Hepatitis B, Chronic","enrollment":5000},{"nctId":"NCT06900166","phase":"PHASE4","title":"Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-04-01","conditions":"Chronic Hepatitis B","enrollment":360},{"nctId":"NCT06881056","phase":"NA","title":"Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2024-07-17","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":90},{"nctId":"NCT01986712","phase":"","title":"A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma","status":"COMPLETED","sponsor":"St. Luke's Hospital and Health Network, Pennsylvania","startDate":"2013-12","conditions":"Melanoma","enrollment":50},{"nctId":"NCT06802718","phase":"PHASE3","title":"Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-01-01","conditions":"Acute Myeloid Leukemia","enrollment":96},{"nctId":"NCT06777173","phase":"NA","title":"Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Ditan Hospital","startDate":"2023-12-01","conditions":"Chronic Hepatitis b, Immunotherapy","enrollment":180},{"nctId":"NCT06707922","phase":"NA","title":"A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"ENROLLING_BY_INVITATION","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2022-03-18","conditions":"Chronic Hepatitis B","enrollment":350},{"nctId":"NCT02001818","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","status":"COMPLETED","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2014-04-11","conditions":"Chronic Myeloid Leukaemia","enrollment":60},{"nctId":"NCT04226950","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-01-10","conditions":"Essential Thrombocytopenia","enrollment":40},{"nctId":"NCT05395507","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-01","conditions":"Essential Thrombocytopenia","enrollment":194},{"nctId":"NCT01340573","phase":"","title":"Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-23","conditions":"Chronic Hepatitis C","enrollment":3},{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT04846491","phase":"PHASE3","title":"A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2019-12-04","conditions":"Chronic Hepatitis B","enrollment":475},{"nctId":"NCT06196632","phase":"","title":"Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-01-06","conditions":"Hepatitis B, Chronic","enrollment":1000},{"nctId":"NCT00574730","phase":"NA","title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-05-23","conditions":"Non-Hodgkins Lymphoma","enrollment":27},{"nctId":"NCT00846430","phase":"PHASE2","title":"Medical Treatment of \"High-Risk\" Neurofibromas","status":"COMPLETED","sponsor":"Corewell Health West","startDate":"2008-10","conditions":"Neurofibromatosis 1","enrollment":9},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT05988879","phase":"","title":"Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients","status":"RECRUITING","sponsor":"Guangzhou 8th People's Hospital","startDate":"2023-08-02","conditions":"AIDS, Hepatitis B","enrollment":60},{"nctId":"NCT01935089","phase":"PHASE2","title":"Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2013-08-07","conditions":"HIV-1 Infection","enrollment":20},{"nctId":"NCT00049530","phase":"PHASE2","title":"PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-01-13","conditions":"Melanoma (Skin)","enrollment":32},{"nctId":"NCT05922306","phase":"EARLY_PHASE1","title":"Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2023-07","conditions":"Hepatitis B, Chronic","enrollment":1084},{"nctId":"NCT00134030","phase":"PHASE3","title":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-11-14","conditions":"Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1334},{"nctId":"NCT05671315","phase":"NA","title":"A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients","status":"RECRUITING","sponsor":"Qing XIe","startDate":"2019-07-03","conditions":"Chronic Hepatitis B, Intermediate to High Risk of HCC","enrollment":267},{"nctId":"NCT03771677","phase":"NA","title":"To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-01","conditions":"Hepatitis B","enrollment":400},{"nctId":"NCT05792761","phase":"NA","title":"A Study on Antiviral Treatment of Chronic Hepatitis B in Children","status":"UNKNOWN","sponsor":"Fang Wang","startDate":"2021-05-06","conditions":"Chronic HBV Infection","enrollment":1900},{"nctId":"NCT02634294","phase":"PHASE2, PHASE3","title":"Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-08","conditions":"Hematological Neoplasms, Recurrence","enrollment":30},{"nctId":"NCT00573378","phase":"PHASE2","title":"Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-09","conditions":"Chronic Myeloid Leukemia","enrollment":12},{"nctId":"NCT02218164","phase":"PHASE2","title":"Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-08-12","conditions":"Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell","enrollment":8},{"nctId":"NCT02089685","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-17","conditions":"Renal Cell Carcinoma, Melanoma","enrollment":295},{"nctId":"NCT01678131","phase":"PHASE1","title":"Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-30","conditions":"Chronic Hepatitis C","enrollment":31},{"nctId":"NCT05490836","phase":"NA","title":"Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2022-09","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT05466565","phase":"","title":"Antiviral Therapy for Patients With Liver Cancer After Surgery","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2021-12-01","conditions":"Hepatocellular Carcinoma","enrollment":360},{"nctId":"NCT01387763","phase":"PHASE3","title":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","status":"COMPLETED","sponsor":"Thomas Stauffer Larsen","startDate":"2012-01","conditions":"Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis","enrollment":202},{"nctId":"NCT04943679","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-06-15","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT01959633","phase":"PHASE1, PHASE2","title":"Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation","status":"COMPLETED","sponsor":"Fondazione Melanoma Onlus","startDate":"2014-04-03","conditions":"Melanoma","enrollment":11},{"nctId":"NCT02982720","phase":"PHASE2","title":"Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron","status":"TERMINATED","sponsor":"Aiwu Ruth He, MD","startDate":"2017-07-05","conditions":"Advanced Cholangiocarcinoma","enrollment":4},{"nctId":"NCT02343224","phase":"PHASE2","title":"Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-11","conditions":"Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas","enrollment":9},{"nctId":"NCT05203055","phase":"PHASE1, PHASE2","title":"Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia","status":"UNKNOWN","sponsor":"Fuzhou General Hospital","startDate":"2021-12-10","conditions":"Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia","enrollment":300},{"nctId":"NCT04382937","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2016-01-12","conditions":"Chronic Hepatitis C Virus Infection","enrollment":222},{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"HIV Infections, Hepatitis C","enrollment":262},{"nctId":"NCT00006325","phase":"PHASE1","title":"Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00015652","phase":"NA","title":"Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":24},{"nctId":"NCT00381953","phase":"PHASE3","title":"High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2003-02","conditions":"Hepatitis C","enrollment":33},{"nctId":"NCT03588715","phase":"PHASE1","title":"Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)","status":"UNKNOWN","sponsor":"Luis Montaner","startDate":"2020-06-18","conditions":"HIV, HIV/AIDS, HIV-1 Infection","enrollment":15},{"nctId":"NCT02218047","phase":"PHASE3","title":"AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2014-11","conditions":"Polycythemia Vera","enrollment":170},{"nctId":"NCT02112032","phase":"PHASE1","title":"Treatment of Advanced Melanoma With MK-3475 and Peginterferon","status":"COMPLETED","sponsor":"Hassane M. Zarour, MD","startDate":"2014-07-24","conditions":"Melanoma","enrollment":43},{"nctId":"NCT03181113","phase":"","title":"Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2016-05-18","conditions":"Hepatitis B","enrollment":473},{"nctId":"NCT00910624","phase":"PHASE3","title":"Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-06-22","conditions":"Hepatitis C, Chronic","enrollment":168},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT01590225","phase":"PHASE3","title":"Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-28","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00525031","phase":"PHASE2","title":"Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08","conditions":"Melanoma","enrollment":55},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT02174172","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-18","conditions":"Solid Cancers","enrollment":158},{"nctId":"NCT01964300","phase":"PHASE2","title":"Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery","status":"TERMINATED","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2014-04-01","conditions":"Childhood Craniopharyngioma","enrollment":19},{"nctId":"NCT01872442","phase":"PHASE2","title":"Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2013-10-15","conditions":"Chronic Phase of Chronic Myeloid Leukemia","enrollment":""},{"nctId":"NCT02379195","phase":"PHASE1, PHASE2","title":"Peginterferon and TIL Therapy for Metastatic Melanoma","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2014-11","conditions":"Metastatic Melanoma","enrollment":12},{"nctId":"NCT01364090","phase":"PHASE4","title":"A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":93},{"nctId":"NCT00919633","phase":"PHASE2","title":"Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C","status":"COMPLETED","sponsor":"Medtronic Corporate Technologies and New Ventures","startDate":"2009-06","conditions":"Hepatitis C","enrollment":116},{"nctId":"NCT03547154","phase":"PHASE2, PHASE3","title":"Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-10-22","conditions":"Chronic Myelogenous Leukemia","enrollment":344},{"nctId":"NCT03552549","phase":"PHASE2, PHASE3","title":"SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-08-05","conditions":"Melanoma","enrollment":126},{"nctId":"NCT03554005","phase":"PHASE1","title":"Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1997-12-29","conditions":"Neoplasms","enrollment":29},{"nctId":"NCT02247440","phase":"PHASE4","title":"HCV-HIV Co-infected Patient Cohort in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2014-08","conditions":"Hepatitis C Infection, HIV","enrollment":18},{"nctId":"NCT03920605","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-02-01","conditions":"Hepatitis B, Liver Fibrosis","enrollment":100},{"nctId":"NCT01295515","phase":"PHASE1, PHASE2","title":"Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-11","conditions":"HIV Infection","enrollment":7},{"nctId":"NCT03919565","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-02-01","conditions":"Hepatitis B, Liver Fibrosis","enrollment":120},{"nctId":"NCT03537274","phase":"PHASE2, PHASE3","title":"Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1997-08-05","conditions":"Hepatitis C","enrollment":1224},{"nctId":"NCT01502696","phase":"PHASE3","title":"Adjuvant PEG Intron in Ulcerated Melanoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2012-10","conditions":"Ulcerated Melanomas","enrollment":1200},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT03801538","phase":"PHASE4","title":"The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-01-01","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT02745704","phase":"PHASE4","title":"The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-04","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT02838810","phase":"PHASE4","title":"The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-06","conditions":"Chronic Hepatitis B","enrollment":200},{"nctId":"NCT01532843","phase":"PHASE4","title":"Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2012-06","conditions":"Chronic Hepatitis B","enrollment":82},{"nctId":"NCT01933906","phase":"PHASE1","title":"Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2013-08-30","conditions":"Chronic Phase Chronic Myeloid Leukemia","enrollment":12},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT00791271","phase":"PHASE1","title":"Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-09-02","conditions":"Melanoma","enrollment":17},{"nctId":"NCT00037882","phase":"PHASE2","title":"PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-02","conditions":"Leukemia, Myeloid, Philadelphia-Positive","enrollment":1},{"nctId":"NCT01606800","phase":"PHASE4","title":"Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-01","conditions":"Hepatitis C, Chronic","enrollment":45}],"_emaApprovals":[],"_faersSignals":[{"count":975,"reaction":"FATIGUE"},{"count":900,"reaction":"NAUSEA"},{"count":899,"reaction":"ANAEMIA"},{"count":771,"reaction":"WEIGHT DECREASED"},{"count":737,"reaction":"VOMITING"},{"count":675,"reaction":"ASTHENIA"},{"count":653,"reaction":"DEHYDRATION"},{"count":598,"reaction":"DEPRESSION"},{"count":587,"reaction":"PYREXIA"},{"count":572,"reaction":"HEADACHE"}],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PEG interferon Alfa-2b 0.5mcg/kg weekly"],"phase":"marketed","status":"active","brandName":"PEG -Intron","genericName":"PEG -Intron","companyName":"Beth Israel Deaconess Medical Center","companyId":"beth-israel-deaconess-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG-Intron is a pegylated interferon alfa-2b that enhances and prolongs the antiviral immune response by binding to interferon receptors on immune cells. Used for Chronic hepatitis C virus (HCV) infection, typically in combination with ribavirin, Chronic hepatitis B virus (HBV) infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}